Pfizer 出了一个90%有效的疫苗，11月底才能供货， 就成了大新闻；中国的陈薇团队，早在2月份就出了100%有效的疫苗，却无人问津

[茶马盐铁]

 

[Chewy]

的确双重标准，也谢天谢地，是双重标准。

陈薇的一期，是三月份做的；二期四月份，官方数据， 508位志愿者接种。 背后的康希诺生物，2009年成立，之前唯一产品，埃博拉病毒疫苗，是从加拿大NRC买的技术，合法技术转换。关于两针100%有效这个结论，我没看到出处。

辉瑞+BNTX, 二期实验参与者 43,538 名。关于 90%+ 有效这个结论，是独立的第三方做出来的。今晚CNN的Wolf采访福奇，福奇特别指出: by an independent organization.

不光是疫苗，学术界对于中国的数据普遍怀疑。原因嘛，呵呵，前段时间清华大学弄一帮专家做了评估，然后就是世界一流大学了。一样的道理。

说尊重，有点矫情。可Reputation这个事情，的确存在。到底可不可靠，内行比我们清楚---CNN这类媒体，都有自己的医学团队。

 

[臭农民]

打人不打脸，你们太过分了。。。。

 

[春夏秋鼕]

有无链接，网上吸引眼球自媒体太多，专门骗傻叉

 

[向问天]

我说的中国政府没说100%。
某些公司吹牛逼不算。

 

[laurie]

你真扫兴。

你挺有人气啊。
他们懂不懂你没事，讨论讨论挺好。

 

[brake rotor]

今天这个interim analysis是基于94个病人得出的结果，但也建议了疫苗研究向着好的方向进展。大家再等等吧，12月初会有更多的数据。
“Upon the conclusion of those discussions, the evaluable case count reached 94 and the DMC performed its first analysis on all cases. The case split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90%, at 7 days after the second dose.”

 

[woodwolf]

呐， 我们的关心焦点根本不在一个点上。 OK？

我不在乎疫苗是否真假， 中国疫苗可以是真，可以是假， 辉瑞制药的疫苗也可以是真， 也可以是假。 这个我不关心。

我一再重申的焦点， 我不明白你们为什么视而不见：

中国在2月份就已经宣布研制生产了有效疫苗；
辉瑞直到11月份才宣布生产出了有效疫苗

中国宣布两次注射疫苗以后， 能够达到100%保护；
辉瑞宣布的也是两次注射， 但是只能达到90%的保护；

你们要的出处， 我都给出来了。

我不跟你辩论真假， 我就问题， 现在大家都不是专家， 都无法冲到实验室去验证真假， 问题是， 两个新闻都出来了。

那些不是专家的记者们， 不是专家的股票经纪们， 为什么相信11月份的90%， 而无视2月份的100%？

这不是双标是什麽？

二月份进行的是一期临床试验，接种疫苗后100%诱导出了抗体。二期临床试验是安全性试验，看接种疫苗后人体有无不良反应，也就是有无副作用。这两期都是很小规模的试验。第三期是有效性试验，需要大规模招募志愿者 （一半人接疫苗，一半人接安慰剂），然后回到发病区自然感染病毒。要知道即使在美国自然感染病毒的人的比例也很低 （美国三亿多人，到目前也只有一千万人感染），假设一万五千人接疫苗，一万五千人接水，接种水的也就二、三白人感病。假设接种水的二百人感病，接疫苗的二十人感病，有效率就到达了90%。现在明白了吗？病毒在中国基本不存在了，所以做不了三期试验。

 

[eetimes]

(Bloomberg) -- The final-stage trial of a Chinese frontrunner vaccine candidate has been halted in Brazil due to a serious adverse event, the first time that any of the Asian nation’s rapidly developed Covid-19 shots have met with such a setback.

Testing of Sinovac Biotech Ltd.’s vaccine, called Coronavac, has been halted in Brazil after an event that occurred on Oct. 29, said the Brazil Health Agency on Tuesday, without any further detail on the illness. The study is interrupted in accordance with regulations while the agency analyzes if the study should continue, it said.

Serious adverse events that occur in drug trials include death, immediate risk of death, long term or serious incapacitation, and hospitalization.

Such pauses are not uncommon in large-scale drug trials and two western developers - AstraZeneca (NYSE:AZN) Plc and Johnson & Johnson -- have paused their vaccine trials in recent months due to serious adverse events, only to re-start them after investigation.

But China has already started administering its vaccines, including Coronavac, to hundreds of thousands of people under an expansive emergency use approval, making the prospect of a safety issue being detected at this stage more concerning.

China Defends Giving Experimental Vaccines to Thousands

Last month, China’s science ministry said its companies have inoculated about 60,000 volunteers in final-stage trials, but there have been no reports of serious adverse events. Sinovac’s company representative did not immediately respond to a request for comment on the Brazil trial pause.

Chinese vaccine developers have been at the forefront of the global race to create an effective immunization against the virus. The push has taken on vital importance as countries look to move beyond Covid-19 and more definitively re-open their economies.

Vaccine development processes that usually take years have been compressed into months by global players, encouraged by politicians wanting a quick fix to the pandemic that has sickened more than 50 million.

The Chinese setback comes as Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) released early findings showing that a vaccine they are developing prevented more than 90% of symptomatic infections in the trial of tens of thousands of volunteers, boosting hope for a quick neutralization of Covid-19.

(Updates with Sinovac company response in sixth paragraph. An earlier version corrected the date of the serious adverse event in Brazil to Oct. 29)

©2020 Bloomberg L.P.

 

[lindamy]

(Bloomberg) -- The final-stage trial of a Chinese frontrunner vaccine candidate has been halted in Brazil due to a serious adverse event, the first time that any of the Asian nation’s rapidly developed Covid-19 shots have met with such a setback.

Testing of Sinovac Biotech Ltd.’s vaccine, called Coronavac, has been halted in Brazil after an event that occurred on Oct. 29, said the Brazil Health Agency on Tuesday, without any further detail on the illness. The study is interrupted in accordance with regulations while the agency analyzes if the study should continue, it said.

Serious adverse events that occur in drug trials include death, immediate risk of death, long term or serious incapacitation, and hospitalization.

Such pauses are not uncommon in large-scale drug trials and two western developers - AstraZeneca (NYSE:AZN) Plc and Johnson & Johnson -- have paused their vaccine trials in recent months due to serious adverse events, only to re-start them after investigation.

But China has already started administering its vaccines, including Coronavac, to hundreds of thousands of people under an expansive emergency use approval, making the prospect of a safety issue being detected at this stage more concerning.

China Defends Giving Experimental Vaccines to Thousands

Last month, China’s science ministry said its companies have inoculated about 60,000 volunteers in final-stage trials, but there have been no reports of serious adverse events. Sinovac’s company representative did not immediately respond to a request for comment on the Brazil trial pause.

Chinese vaccine developers have been at the forefront of the global race to create an effective immunization against the virus. The push has taken on vital importance as countries look to move beyond Covid-19 and more definitively re-open their economies.

Vaccine development processes that usually take years have been compressed into months by global players, encouraged by politicians wanting a quick fix to the pandemic that has sickened more than 50 million.

The Chinese setback comes as Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) released early findings showing that a vaccine they are developing prevented more than 90% of symptomatic infections in the trial of tens of thousands of volunteers, boosting hope for a quick neutralization of Covid-19.

(Updates with Sinovac company response in sixth paragraph. An earlier version corrected the date of the serious adverse event in Brazil to Oct. 29)

©2020 Bloomberg L.P.

sad news

 

[wilson111]

大家要出处， 出处我已经给了。 对不对？
辉瑞制药的90%， 不也是他们说， 你们大家就这么一听嘛。 你别告诉我CFC上有人杀到德国的实验室，去做了验证了？

那些记者， 那些股市掮客， 难道都是疫苗专家不成？

大家都不是专家， 大家都是只能看看转发的报道。

为什么一个就要相信， 一个就要不信呢？明明中国的数据比辉瑞漂亮多了！

这么明显的歧视， 这么明显的双标， 你们都瞎了吗？

pat pat。没必要上这么大火，喷你的人明显没get到你的点。

我帮你举个栗子， 这就像期末考试，一个不合群的人大声宣称，我数学考了满分，然后没人理他，一个合群的人大声宣布我考了90分！然后一群人跑过来说，你太厉害，怎么考的，给我传授传授经验呗。

可笑的是，实际上没有一个人去验证不合群和合群的人每人实际考了多少分，有没有说谎。

不扯别的，这就是赤裸裸的双标。

不过话又说回来，没啥大利益冲突的人与人之间都是这样的，我们还能指望代表不同阵营的利益团体一碗水端平么？难啊！

 

[茶马盐铁]

pat pat。没必要上这么大火，喷你的人明显没get到你的点。

我帮你举个栗子， 这就像期末考试，一个不合群的人大声宣称，我数学考了满分，然后没人理他，一个合群的人大声宣布我考了90分！然后一群人跑过来说，你太厉害，怎么考的，给我传授传授经验呗。

可笑的是，实际上没有一个人去验证不合群和合群的人每人实际考了多少分，有没有说谎。

不扯别的，这就是赤裸裸的双标。

不过话又说回来，没啥大利益冲突的人与人之间都是这样的，我们还指望代表不同阵营的利益团体能一碗水端平么？难啊！

所以以后不要扯人类命运共同体的蛋

 

[superlover]

pat pat。没必要上这么大火，喷你的人明显没get到你的点。

我帮你举个栗子， 这就像期末考试，一个不合群的人大声宣称，我数学考了满分，然后没人理他，一个合群的人大声宣布我考了90分！然后一群人跑过来说，你太厉害，怎么考的，给我传授传授经验呗。

可笑的是，实际上没有一个人去验证不合群和合群的人每人实际考了多少分，有没有说谎。

不扯别的，这就是赤裸裸的双标。

不过话又说回来，没啥大利益冲突的人与人之间都是这样的，我们还能指望代表不同阵营的利益团体一碗水端平么？难啊！

今天新闻据说中国疫苗第三期实验在巴西叫停了，因为致命的副作用云云。。。是哪种我不知

 

[peterchen]

加拿大已购辉瑞疫苗2000万剂 杜鲁多：看到曙光​

总理杜鲁多今天在得知美国制药公司辉瑞（Pfizer）的COVID-19候选疫苗可能有效的消息后，表示终于看到了“曙光”。
但是，他敦促人们不要放松警惕，因为疫苗对于预防COVID-19可能90％有效的数据，是初步的，而且距离任何候选疫苗大规模上市，还要等几个月的时间

 

[茶马盐铁]

加拿大已购辉瑞疫苗2000万剂 杜鲁多：看到曙光​

总理杜鲁多今天在得知美国制药公司辉瑞（Pfizer）的COVID-19候选疫苗可能有效的消息后，表示终于看到了“曙光”。
但是，他敦促人们不要放松警惕，因为疫苗对于预防COVID-19可能90％有效的数据，是初步的，而且距离任何候选疫苗大规模上市，还要等几个月的时间

按照他们的生产规模， 加拿大几个月内可拿不到啊。 我看这个架势， 加拿大通知群众去接种疫苗，怎么也得到明年夏天了。

可能最后还得把技术交给中国去生产， 才能满足普通大众的需要。 问题是这东西必须在-20度的环境下存储和运输。 让中国把疫苗运出来，这非常困难。
大家排队去中国打吧。